Abstract: The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.

Abstract: The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.

Abstract: Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.

Abstract: The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.

Abstract: Fusion polypeptides with modified multimerization domains that provide high expression, solubility, stability, and low immunogenicity to the fusion polypeptides have been developed. TRAIL compositions with the modified multimerization domains show improved physico-chemical and biological properties relative to TRAIL compositions with unmodified multimerization domains. The TRAIL compositions also have lower immunogenicity in the mammalian host when compared to that of TRAIL compositions with unmodified multimerization domains. The TRAIL compositions induce apoptosis of cancer cells and cancer-associated fibroblasts in vivo, reducing tumor size.

Abstract: Fusion polypeptides with modified multimerization domains that provide high expression, solubility, stability, and low immunogenicity to the fusion polypeptides have been developed. TRAIL compositions with the modified multimerization domains show improved physico-chemical and biological properties relative to TRAIL compositions with unmodified multimerization domains. The TRAIL compositions also have lower immunogenicity in the mammalian host when compared to that of TRAIL compositions with unmodified multimerization domains. The TRAIL compositions induce apoptosis of cancer cells and cancer-associated fibroblasts in vivo, reducing tumor size.

Abstract: In one aspect, GLP-1r agonists including long-acting PEGylated exenatide (NLY01), exenatide, liraglutide, exenatide LAR (long acting), taspoglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, LY2189265 are used to treat ocular ischemic, inflammatory, angiogenic, and/or degenerative conditions.

Abstract: Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.

Abstract: The present invention relates to methods for sensitizing cancers to death receptor agonist therapies, comprising use of one or more kinase inhibitors. Such kinase inhibitors can be administered and identified as effective for sensitizing to death receptor agonist therapy in vitro or in vivo. Screening for additional kinase inhibitors and other agents that sensitize cancer cells to death receptor agonists is also contemplated, as is preventing and/or treatment of cancer using combination therapies that include such agents (e.g., kinase inhibitor(s) and death receptor agonist(s)). Formulations and kits including such combined agents are also contemplated and described, as are diagnostic/imaging agents that allow for advanced tracking of therapeutic outcome.

Abstract: The present disclosure relates to methods and compositions for treating and/or preventing autoimmune fibrosis, such as systemic sclerosis (SSc; scleroderma). The method includes administering to a subject in need thereof an effective amount of a death receptor agonist. Suitable death receptor agonists include tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), agonistic death receptor antibodies, and variants, analogues, or derivatives thereof. The administration of the death receptor agonist blocks fibroblast or profibrogenic cell activation, and/or reduces or depletes myofibroblasts, thereby reducing or preventing systemic sclerosis.

Abstract: The present disclosure relates to methods and compositions for treating and/or preventing autoimmune fibrosis, such as systemic sclerosis (SSc; scleroderma). The method includes administering to a subject in need thereof an effective amount of a death receptor agonist. Suitable death receptor agonists include tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), agonistic death receptor antibodies, and variants, analogues, or derivatives thereof. The administration of the death receptor agonist blocks fibroblast or profibrogenic cell activation, and/or reduces or depletes myofibroblasts, thereby reducing or preventing systemic sclerosis.

Abstract: The present invention comprises pegylated TRAIL peptides and their use in conjunction with various TRAIL sensitizing agents in tumor homing nanoparticle formulations for use in the treatment of cancer in a subject.